cirrhosis bpc 157 Protecting and Repairing the Body with BPC-157 Stable Gastric Pentadecapeptide BPC 157
Description
As a network of tightly interconnected evidence, this can provide a consistent background for the obtained pleiotropic beneficial effects [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40]
Limited Human Data: Most benefits are derived from animal studies, so long term safety and efficacy in humans remain uncertain
It was originally developed by Metabolic Pharmaceuticals in Australia during the late 1990s as a potential **anti-obesity peptide** that could stimulate fat loss without the growth-promoting or diabetogenic effects of full-length growth hormone
But something has gone wrong
